Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant

被引:127
作者
Colombo, E
Martinelli, P
Zamponi, R
Shing, DC
Bonetti, P
Luzi, L
Volorio, S
Bernard, L
Pruneri, G
Alcalay, M
Pelicci, PG
机构
[1] European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy
[2] European Inst Oncol, Div Pathol, I-20141 Milan, Italy
[3] Univ Milan, IFOM Inst, Milan, Italy
[4] Univ Milan, Dept Med Surg & Dent, Milan, Italy
关键词
D O I
10.1158/0008-5472.CAN-05-2378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One third of acute myeloid leukemias (AMLs) are characterized by the aberrant cytoplasmic localization of nucleophosmin (NPM) due to mutations within its putative nucleolar localization signal. NPM mutations are mutually exclusive with major AML-associated chromosome rearrangements and are frequently associated with a normal karyotype, suggesting that they are critical during leukemogenesis. The underlying molecular mechanisms are, however, unknown. NPM is a nucleocytoplasmic shuttling protein that has been implicated in several cellular processes, including ribosome biogenesis' centrosome duplication, cell cycle progression, and stress response. It has been recently shown that NPM is required for the stabilization and proper nucleolar localization of the tumor suppressor p19(Arf). We report here that the AML-associated NPM mutant localizes mainly in the cytoplasm due to an alteration of its nucleus-cytoplasmic shuttling equilibrium, forms a direct complex with p19(Arf), but is unable to protect it from degradation. Consequently, cells or leukemic blasts expressing the NPM mutant have low levels of cytoplasmic Arf. Furthermore, we show that expression of the NPM mutant reduces the ability of Arf to initiate a p53 response and to induce cell cycle arrest. Inactivation of p19(Arf), a key regulator of the p53-dependent cellular response to oncogene expression, might therefore contribute to leukemogenesis in AMLs with mutated NPM.
引用
收藏
页码:3044 / 3050
页数:7
相关论文
共 29 条
[1]   Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23 [J].
Bertwistle, D ;
Sugimoto, M ;
Sherr, CJ .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (03) :985-996
[2]   Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis [J].
Bischof, D ;
Pulford, K ;
Mason, DY ;
Morris, SW .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (04) :2312-2325
[3]   MAJOR NUCLEOLAR PROTEINS SHUTTLE BETWEEN NUCLEUS AND CYTOPLASM [J].
BORER, RA ;
LEHNER, CF ;
EPPENBERGER, HM ;
NIGG, EA .
CELL, 1989, 56 (03) :379-390
[4]   An intact HDM2 RING-finger domain is required for nuclear exclusion of p53 [J].
Boyd, SD ;
Tsai, KY ;
Jacks, T .
NATURE CELL BIOLOGY, 2000, 2 (09) :563-568
[5]  
CHANG JH, 1989, J BIOL CHEM, V264, P11732
[6]   Nucleophosmin is required for DNA integrity and p19Arf protein stability [J].
Colombo, E ;
Bonetti, P ;
Denchi, EL ;
Martinelli, P ;
Zamponi, R ;
Marine, JC ;
Helin, K ;
Falini, B ;
Pelicci, PG .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (20) :8874-8886
[7]   Nucleophosmin regulates the stability and transcriptional activity of p53 [J].
Colombo, E ;
Marine, JC ;
Danovi, D ;
Falini, B ;
Pelicci, PG .
NATURE CELL BIOLOGY, 2002, 4 (07) :529-533
[8]   Detection of normal and chimeric nucleophosmin in human cells [J].
Cordell, JL ;
Pulford, KAF ;
Bigerna, B ;
Roncador, G ;
Banham, A ;
Colombo, E ;
Pelicci, PG ;
Mason, DY ;
Falini, B .
BLOOD, 1999, 93 (02) :632-642
[9]   Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. [J].
Falini, B ;
Mecucci, C ;
Tiacci, E ;
Alcalay, M ;
Rosati, R ;
Pasqualucci, L ;
La Starza, R ;
Diverio, D ;
Colombo, E ;
Santucci, A ;
Bigerna, B ;
Pacini, R ;
Pucciarini, A ;
Liso, A ;
Vignetti, M ;
Fazi, P ;
Meani, N ;
Pettirossi, V ;
Saglio, G ;
Mandelli, F ;
Lo-Coco, F ;
Pelicci, P ;
Martelli, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :254-266
[10]   Sedimentation analyses of the salt- and divalent metal ion-induced oligomerization of nucleolar protein B23 [J].
Herrera, JE ;
Correia, JJ ;
Jones, AE ;
Olson, MOJ .
BIOCHEMISTRY, 1996, 35 (08) :2668-2673